EGFR Degrader Compounds for Drug-Resistant Mutant Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EGFR tyrosine kinase inhibitors face challenges in effectively targeting drug-resistant mutants, such as T790M, L858R, and C797S, leading to treatment resistance in cancers like non-small cell lung cancer, and there is a need for new therapeutic agents that work differently to overcome these mutations.
Innovation Solution
Development of compounds that degrade EGFR via the ubiquitin proteasome pathway by binding to the EGFR protein and utilizing an E3 Ligase binding portion, specifically targeting mutated forms like T790M, L858R, and C797S through a Targeting Ligand and Linker system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional EGFR tyrosine kinase inhibitors are used, then they can inhibit EGFR activity, but they fail to effectively target drug-resistant mutants like T790M, L858R, and C797S
Solution Approach 1:
The patent changes the mechanism of action from reversible inhibition to irreversible degradation. The compounds are designed to induce proteasomal degradation of EGFR through a unique mechanism involving covalent binding to C797 and recruitment of the ubiquitin-proteasome system, thereby overcoming resistance to traditional reversible inhibitors that cannot effectively target mutant forms.
Solution Approach 2:
The patent introduces an intermediary mechanism involving the ubiquitin-proteasome system. The compounds act as degraders that recruit E3 ubiquitin ligases to tag EGFR for degradation, rather than directly blocking the kinase active site. This intermediary approach allows selective degradation of mutant EGFR forms that are resistant to conventional inhibitors.
2Reliability
If reversible EGFR inhibitors are used, then they can be administered, but treatment resistance arises frequently due to secondary mutations like T790M and C797S
Solution Approach 1:
The patent employs preliminary action by designing compounds that form irreversible covalent bonds with the C797 cysteine residue of EGFR mutants. This covalent binding permanently inactivates the target protein and prevents future resistance mutations from developing, as the protein is degraded rather than merely inhibited. The effect persists until new EGFR protein is synthesized.
Solution Approach 2:
The patent utilizes the cell's own proteasomal degradation machinery to permanently eliminate the target protein. Once the degrader compound binds and recruits the ubiquitin-proteasome system, the EGFR mutant is degraded and removed from the system, creating a long-lasting effect that does not depend on continuous drug presence.
3Reliability
If mutant-selective irreversible inhibitors are used, then they are highly active against T790M mutant, but efficacy is compromised by acquired C797S mutation
Solution Approach 1:
The patent inverts the conventional approach by targeting C797 for covalent binding rather than trying to accommodate the C797S mutation. The compounds are designed to bind covalently to wild-type C797, inducing degradation of the protein. When C797S mutation occurs, the mutant protein is degraded along with the wild-type, preventing the mutated form from gaining resistance. This inversion strategy turns the resistance mechanism against the cancer cells.
Solution Approach 2:
The patent converts the potential harm of C797S resistance mutation into a benefit. By designing degraders that require C797 for binding, the therapy ensures that any cell acquiring C797S mutation will have its EGFR (both wild-type and mutant) degraded, thereby eliminating the resistant clone. The mutation that would normally confer resistance becomes a marker for enhanced degradation and cell death.
4Reliability
If EGFR degradation compounds are used, then they provide selective degradation of mutants, but may require optimization of dosage and timing
Solution Approach 1:
The patent employs a multi-functional compound design where a single molecule performs multiple functions: (1) covalent binding to C797 of EGFR mutants, (2) recruitment of E3 ubiquitin ligases, (3) induction of ubiquitination, and (4) triggering proteasomal degradation. This universality simplifies the overall therapeutic approach despite the complexity of the degradation mechanism.
Solution Approach 2:
The patent utilizes the cell's own degradation machinery (ubiquitin-proteasome system) to perform the actual protein destruction. The compound only needs to initiate the process by binding and recruiting E3 ligases; the cell then autonomously completes the degradation, eliminating the need for external delivery systems or complex administration protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide selective degradation of EGFR mutants, overcoming resistance and potentially requiring less dosage, prolonging drug effect, and targeting all protein functions, offering improved efficacy and safety over traditional inhibitors.
Implementation Method 1
The compounds provide selective degradation of EGFR mutants, overcoming resistance and potentially requiring less dosage, prolonging drug effect, and targeting all protein functions
Implementation Method 2
The compounds are useful for the treatment of various cancers by degrading the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation
Data Source
AI summary
The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.